While some studies have focused on patients with EGFR mutations [8, 9], it remains unclear whether patients with stage IIIB–IV NSCLC without EGFR or ALK mutations have a different prognosis according to the disease stage at the time of the initial diagnosis. This evidence concerns the gene ALK and non-small cell lung carcinoma.